Industries > Pharma > Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

PUBLISHED: 21 September 2018
PAGES: 135
PRODUCT CODE: PHA0332
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0332 Categories: , Tags: , ,

The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 135-page report you will receive 92 charts– all unavailable elsewhere.

The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Acute Myeloid Leukaemia Market from 2018-2028

• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
North America: US, Canada, and Mexico
Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva

• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

Visiongain’s study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.

Buy our report today Acute Myeloid Leukaemia Market Analysis : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ